PubMed Health⌕ Search

Biomedical subjects

H G Dammann

Publications and source records attributed to H G Dammann.

At least 109 records · Page 6Linked to original sources
PubMed1986

[Rioprostil 600 micrograms at night: marked inhibition of nocturnal intragastric acidity in man].

Antisecretory doses of prostaglandin analogues of the E1 and E2 series have been shown to promote peptic ulcer healing. In this double blind randomized cross-over study we investigated the effect of oral Rioprostil 300 micrograms b.i.d., 600 micrograms hs and placebo on 24 h intragastric H+ activity in 9 healthy male volunteers (age 20-37 years). 5-10 ml of gastric contents were aspirated hourly via a nasogastric tube. The pH of the samples was determined using a glass electrode . The results were expressed in terms of H+ activity (mmol/l). Night acidity (AUC/h, 2400-0800) is decreased by rioprostil in a dose related fashion (300 micrograms: 52%, 600 micrograms: 74%). The effect on day-time (0900-1800) H+ activity is much less. Rioprostil 300 micrograms given at breakfast reduce day-time acidity by 33%. Our results suggest that 600 micrograms Rioprostil in a single bedtime dose is effective in peptic ulcer treatment.

Adult↗
PubMed1986

[Stomach ulcer healing with enprostil, an orally effective prostaglandin E2 analog: direct comparative study with ranitidine].

In a randomized, endoscopically controlled double-blind trial the effectiveness of a twice daily dose of the prostaglandin E2-analogue enprostil was compared with ranitidine given to 93 ambulatory patients with benign gastric ulcers. Under 35 micrograms b.i.d. enprostil the ulcer healing rates after 2, 4, 6 and 8 weeks averaged 22% (10/46), 58% (26/45), 80% (35/44) and 86% (37/43). The corresponding values for ranitidine 150 mg b.i.d. were 22% (10/46), 66% (29/44), 84% (38/45) and 89% (41/46). The differences were not statistically significant. Both drugs had a similar influence on the ulcer symptoms and were well tolerated. The findings suggest that enprostil can be given in a twice daily dosage in the treatment of benign gastric ulcers.

Clinical Trials as Topic↗
PubMed1986

[Enprostil in the acute treatment of duodenal ulcer: direct comparative study with pirenzepin].

In a randomized, endoscopically controlled double-blind trial the effectiveness of a twice daily dose of the prostaglandin E2-analogue enprostil was compared with pirenzepine given to 97 ambulatory patients with duodenal ulcers. Under 35 micrograms b.i.d. enprostil the ulcer healing rates after 2, 4 and 6 weeks averaged 41%, 82% and 92%. The corresponding values for pirenzepine were 44%, 72% and 89%. The differences were not statistically significant. Both drugs had a similar influence on the ulcer symptoms.

Acute Disease↗
PubMed1986

Prostaglandins and peptic ulcer disease: nocturnal administration of rioprostil vs ranitidine in duodenal ulcer healing.

Hypochlorhydria induced by potent antisecretory drugs is followed by a marked elevation of serum gastrin levels which leads to changes in ECL cell density in rats. "Soft" antiulcer drugs like prostaglandins do not increase gastrin levels. Their use in peptic ulcer disease seems to be mainly limited by a relatively high incidence of diarrhea and abdominal cramps. Rioprostil is a new prostaglandin E1 analogue. We compared the potency and duration of action of rioprosil 600 micrograms nocte with 300 micrograms bid on human gastric secretion in a placebo-controlled double-blind study. We further evaluated the clinical effectiveness of rioprostil 600 micrograms nocte in the acute treatment of duodenal ulcer. Nocturnal gastric acidity (24:00 to 08:00) was inhibited from 54.5 +/- 1.7 mmol H+/L (placebo experiments; n =9) to 26.7 +/- 3.5 mmol H+/L (52%) by rioprostil 300 micrograms bid (p less than 0.05) and to 14.4 +/- 3.8 mmol H+/L (74%) by rioprostil 600 micrograms nocte (p less than 0.05). During the daytime (09:00 to 18:00), H+ activity was reduced by 33% and 15% respectively (n.s.). Two hundred and three patients with endoscopically proven duodenal ulcers were randomly allocated to treatment with either rioprostil 600 micrograms nocte or ranitidine 300 mg nocte for 4 weeks in a prospective double-blind study. The two groups were similar. After 2 and 4 weeks treatment respectively, about 55% and 85% of patients healed on rioprostil 600 micrograms nocte and 55% and 90% on ranitidine 300 mg nocte. There were no differences between the treatment groups in ulcer pain relief.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1986

[Intragastric acidity under the prostaglandin E2 analog trimoprostil. Increased inhibitory effect through administration after meals].

In this double-blind cross-over study the effect of trimoprostil (trimethyldesoxyprostaglandin E2), an orally effective prostaglandin E2 analogue, on 24-h intragastric H+-activity, nocturnal acid output, nocturnal volume secretion and meal stimulated gastrin secretion was determined in 12 healthy male volunteers. On three different days the subjects received four times a day either placebo or 1.5 mg trimoprostil 30 min before or 30 min after meals. Trimoprostil administered before or after meals reduced 24-h intragastric acidity by 27.0 and 53.9%. Nocturnal acid output was inhibited by 32.7 and 55.6%. Nocturnal volume secretion and meal stimulated gastrin secretion remained unaffected. The study shows that the antisecretory activity is significantly increased when trimoprostil is given after meals.

Administration, Oral↗
PubMed1986

[A comparative gastroscopic study of lonazolac and indomethacin in healthy subjects].

In 9 healthy volunteers the effects of a 14-day treatment with lonazolac 300 mg b.i.d. on gastric and duodenal mucosa have been endoscopically compared with those of indomethacin 75 mg b.i.d. in a double-blind placebo-controlled trial. Lonazolac and indomethacin induced significantly more gastric and duodenal mucosal injuries (1.9 +/- 0.4 and 1.7 +/- 0.3) compared to placebo (0.9 +/- 1.0) (p less than 0.05). The validity of different procedures in predicting the deleterious effects of nonsteroidal antiinflammatory drugs on the human upper gastrointestinal epithelium is discussed.

Adult↗
PubMed1986

[Dose-dependent telenzepine inhibition of the secretion of human gastric acid stimulated by sham feeding and saliva].

The effect of graded doses of the new antimuscarinic agent telenzepine on human gastric secretion has been studied in a double-blind placebo-controlled trial in nine healthy volunteers. Over a period of 60 minutes basal acid output as well as acid response to sham feeding was examined. Telenzepine reduced dose-dependently basal acid secretion: This parameter was inhibited with 1 mg by 2%, with 2 mg by 37%, with 3 mg by 53% and with 5 mg by 76%, respectively. The corresponding values for stimulated acid secretion were 16%, 34%, 40% and 57%, respectively. The reduction of basal and stimulated acid secretion was statistically significant (p less than 0.05) following the two larger telenzepine doses. Production of saliva was inhibited by 9%, 21%, 28% and 48%, respectively. The latter reaching statistical significance (p less than 0.05).

Adult↗
PubMed1986

[Effect of FCE 20,700, an effective oral prostaglandin E2 analog on the human gastric mucosa epithelium].

In randomised double-blind crossover studies the effect of FCE 20700, an oral effective PG E2-analogue, has been evaluated on human gastric secretion, on the behaviour of transmucosal gastric potential difference against acetylsalicylic acid as well as on indomethacin-evoked mucosal lesions of stomach and duodenum in healthy volunteers. Single doses of 500 micrograms and 1500 micrograms FCE 20700 inhibited basal acid output without affecting pentagastrin maximally stimulated acid secretion. Both doses of this prostaglandin analogue prevented completely the drop in gastric potential difference brought about by 1000 mg acetylsalicylic acid. Concomitant administration of 250 micrograms t.i.d. and 750 micrograms t.i.d. FCE 20700 did not reduce the lesion score induced by 50 mg t.i.d. indomethacin over 6 days.

Administration, Oral↗
PubMed1986

[Gastroduodenal tolerability of indomethacin and acetaminophen. A comparative endoscopic study in healthy subjects].

The effect of a 5- and 10-day treatment with indometacin and acemetacin (Rantudil) on the gastroduodenal mucosa was endoscopically evaluated in 16 healthy volunteers. In a randomised double-blind cross-over fashion the volunteers received 50 mg t.i.d. indometacin as well as 60 mg t.i.d. acemetacin. Acemetacin evoked after 5 and 10 days significantly less gastroduodenal lesions than indometacin. Possible reasons for this apparently better tolerability of acemetacin in man are discussed.

Acetaminophen↗
PubMed1985

[Healing rates following omeprazole and ranitidine treatment of gastric ulcer. Results of a German multicenter study].

The effectiveness of omeprazole (20 mg orally each morning) or ranitidine (150 mg orally twice daily) in the treatment of gastric ulcer was compared in 184 out-patient in a randomized, endoscopically controlled multi-centre double-blind ("double dummy") trial. Healing rates with omeprazole after two, four and eight weeks were 43, 81 and 95%, respectively, those with ranitidine were 45, 80 and 90%, a statistically not significant difference. Independently of medication, small ulcers (less than 8 mm diameter) healed more quickly than larger ones. Ulcers in the body of the stomach responded poorest to both drugs. Smoking had no statistically significant effect on healing rate. Omeprazole and ranitidine had similarly favourable effects on symptoms. Neither side effects nor changes in biochemical parameters could be ascribed to omeprazole. Both drugs had equivalent effects on the healing of gastric ulcers in the stated dosages.

Adult↗
PubMed1985

[Accelerated healing of ulcus ventriculi by a single evening dose of famotidine. Results of an Austrian-German-Italian multicenter study].

An 8 week, double-blind randomized, placebo-controlled multicenter trial was conducted in Austria, Germany and Italy to determine whether famotidine would speed healing and relief of symptoms in patients with benign gastric ulcer. Of the 131 patients who completed the trial, 66 received 40 mg famotidine in the evening and 65 placebo. At 4, 6, and 8 weeks after entry, ulcers had healed in a higher percentage of patients treated with famotidine than of those treated with placebo (47%, 70%, 91% vs 32%, 49%, 61%). In the famotidine group healing had occurred significantly more often after 6 and 8 weeks (p less than 0.05 and p less than 0.01 respectively). Famotidine was superior to placebo in relieving ulcer symptoms. The proportion of patients receiving additional antacid therapy was significantly lower in the famotidine group. The findings suggest that the new H2-receptor antagonist famotidine significantly speeds the healing of benign gastric ulcers in a single evening dose.

Adolescent↗
PubMed1985

[Short-term therapy of duodenal ulcer with omeprazole and ranitidine. Results of a German multicenter study].

In a randomized, endoscopically controlled double-blind trial the effectiveness of a single oral, morning dose of 40 mg omeprazole was compared with a twice daily oral dose of 150 mg ranitidine given to 334 ambulatory patients with duodenal ulcers. Under omeprazole 105 of 146 duodenal ulcers were demonstrated to have healed within 14 days (72%), compared with 95 of 160 (59%) on ranitidine. The difference is statistically significant (P = 0.0121). After 14 days smaller ulcers healed more quickly than large ones, regardless of the drug used: 80 of 110 with diameter 3-5 mm (73%); 48 of 90 with diameter more than 8 mm (53%). Smoking delayed healing [healing rate among non-smokers, 87 of 117 (74%); among smokers, 113 of 189 (60%)]. Healing rates among smokers receiving omeprazole and non-smokers receiving ranitidine were nearly identical. After 4 weeks, at 96 and 92% respectively, there was no difference in regard to healing rate. Both drugs had a similar influence on the symptoms. Thus, for the first time it has been demonstrated that omeprazole is superior to ranitidine after 14-day treatment of duodenal ulcer.

Adolescent↗
PubMed1985

Famotidine versus ranitidine for the short-term treatment of duodenal ulcer.

One-hundred and eight-three patients with endoscopically proven duodenal ulcers, enrolled in this prospective, double-blind study, were randomly allocated to receive famotidine 40 mg once at night, 20 mg twice daily, 40 mg twice daily, or ranitidine 150 mg twice daily for 2-8 weeks. Pretreatment characteristics between the four groups were similar. After 4 weeks of treatment, among the famotidine-treated patients, 38 of 42 (90.5%) healed with the 40 mg once nightly regimen, 35 of 42 (83.3%) with 20 mg twice daily, and 37 of 41 (90.2%) with 40 mg twice daily. In the ranitidine group 40 of 43 patients (93.0%) healed. After 8 weeks of treatment, the respective data were: 97.6, 95.2, 100 and 93.0%. Different results between the famotidine groups and the ranitidine group were not statistically significant. All treatments were well tolerated and severe adverse events were rare. Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with ranitidine, indicating the importance of overnight gastric acidity in the pathogenesis of duodenal ulcer disease.

Adolescent↗
PubMed1985

Famotidine: nocturnal administration for gastric ulcer healing. Results of multicenter trials in Austria and Germany.

We conducted an 8-week, double-blind, randomized, placebo-controlled multicenter trial (Austria and Germany) to determine whether famotidine would speed healing or relief of symptoms in patients with benign gastric ulcer. Of the 65 patients who completed the trial, 32 received famotidine 40 mg once at night, and 33 received placebo. At 4, 6, and 8 weeks after entry, ulcers had healed in a larger percentage of patients treated with famotidine than in those treated with placebo (German multicenter trial: 65 vs. 46%, 95 vs. 71%, and 95 vs. 79%; Austrian multicenter trial: 42 vs. 44%, 67 vs. 44%, and 92 vs. 44%). In the famotidine group, healing had occurred significantly more often after 6 weeks (p less than 0.05). Famotidine was not superior to placebo in relieving ulcer symptoms. The findings suggest that famotidine in a single evening dose significantly hastens the healing of benign gastric ulcers.

Adolescent↗
PubMed1985

[Famotidine versus ranitidine in the acute treatment of duodenal ulcer. A multicenter comparative study in Germany].

185 patients with endoscopically proven duodenal ulcers were randomly allocated to treatment with either famotidine 40 mg nocte, 20 mg bid, 40 mg bid or ranitidine 150 mg bid for 2-8 weeks in a prospective double-blind study. The four groups were similar with regard to age, sex, duration of ulcer disease, smoking habits etc. After 2 weeks treatment 28/42 patients (66.7%) healed on famotidine 40 mg nocte, 24/42 patients (57.1%) on famotidine 20 mg bid, 26/41 patients (63.4%) on famotidine 40 mg bid and 28/43 patients (65,1%) on ranitidine 150 mg bid. The corresponding healing rates after 4 weeks were 90.5%, 83.3%, 90.2% and 93%, respectively. After 8 weeks more than 93% of the patients had healed ulcers. At each time there was no statistical difference between the different famotidine regimens and the ranitidine group. All treatments were well tolerated and severe adverse events were rare. Famotidine 40 mg at night, therefore, appears to be as good as conventional ranitidine.

Adolescent↗